EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA).
Haystack Oncology, Quest Diagnostics Inc.（紐交所：DGX）旗下公司宣佈與Lisata Therapeutics Inc.（納斯達克：LSTA）展開研究合作。
Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules.
Haystack Oncology開發了Haystack MRD，一種基於腫瘤信息的下一代方法，用於測量微小殘留病變。Haystack MRD利用糾錯的ctDNA技術，可以檢測到一百萬個正常DNA分子中的一個ctDNA分子。
Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors.
Lisata Therapeutics是一家臨床階段的製藥公司，致力於開發創新的高級實體瘤治療方案。
Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
根據協議，Lisata將使用Haystack MRD技術在一項針對轉移性胰腺癌的臨床研究中檢測循環腫瘤DNA（ctDNA），評估cerpetpetide聯合化療的探索性治療效果。
In the FORTIFIDE study, Lisata is investigating the safety, tolerability, and efficacy of its lead product candidate, certepetide, when given as a 4-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer.
在FORTIFIDE研究中，Lisata正在調查其主要產品候選藥物certepetide的安全性、耐受性和療效，以作爲目前一線治療標準FOLFIRINOX的進展期轉移性胰腺導管腺癌（mPDAC）患者的輔助治療措施。
As part of this research, Lisata has engaged Haystack to use its MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide.
作爲此項研究的一部分，Lisata已與Haystack合作，在患者治療過程中多次使用MRD檢測技術測量血清ctDNA水平，作爲分析certepetide早期治療效果的探索性終點。
The American Cancer Society estimates more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024. mPDAC accounts for more than 90% of pancreatic cancer cases and is a highly aggressive form of the disease.
美國癌症協會估計，到2024年全國超過66,000人將被診斷出患有胰腺癌。mPDAC佔據了胰腺癌病例的90%以上，是該疾病中高度侵襲性的形式。
Most recently, Lisata Therapeutics announced the early completion of enrollment in its Phase 2a BOLSTER trial evaluating certepetide (formerly LSTA1), Lisata's investigational product, as a treatment for first-line cholangiocarcinoma.
最近，Lisata Therapeutics宣佈旗下LSTA1的探索性藥物cerpetpetide在一線膽道癌治療中早期完成了2a期BOLSTER試驗的招募。
Price Action: DGX shares closed at $148.48, and LSTA shares closed at $3.66 on Wednesday.
DGX股票週三收盤價爲148.48美元，LSTA股票收盤價爲3.66美元。
- Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High.
- 各州法律不一致使僱主在藥物測試政策方面難以應對，藥物測試作弊率達到30年來最高。
譯文內容由第三人軟體翻譯。